Clenil Modulite (Beclometasone Dipropionate)
Is It Right for You?
A complete guide to Clenil Modulite (Beclometasone Dipropionate) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Clenil Modulite?
Clenil Modulite is a pressurised metered-dose inhaler (pMDI) containing beclometasone dipropionate — an inhaled corticosteroid (ICS) used as a preventer (controller) medication for the long-term management of asthma. It is one of the most widely prescribed ICS inhalers in the UK and a core component of the stepwise approach to asthma treatment recommended by national guidelines (BTS/NICE/SIGN).
Clenil Modulite is available in four strengths: 50, 100, 200, and 250 micrograms per actuation. The 50 and 100 mcg strengths are typically used in mild-to-moderate asthma and in children aged 5 and over; the 200 and 250 mcg strengths are used in moderate-to-severe asthma, often as part of step-up therapy alongside a long-acting beta-2 agonist (LABA) or leukotriene receptor antagonist (LTRA). The 'Modulite' formulation uses the HFA (hydrofluoroalkane) propellant, which delivers consistent dosing without the ozone-depleting CFC propellants used in older inhalers.
Clenil is a preventer, not a reliever — it must be used every day to maintain control of airway inflammation, even when symptoms are absent, and does not provide acute relief during asthma attacks. Every patient on Clenil should also have a fast-acting reliever inhaler (such as salbutamol) available at all times.
Clenil Modulite is a prescription-only medication in the UK. A licensed clinician must confirm the diagnosis of asthma, assess severity, choose an appropriate starting dose, and review treatment at least annually as part of structured asthma care.
What Conditions Is Clenil Modulite Used For?
Clenil Modulite is prescribed for the long-term prevention and control of:
Clenil Modulite is licensed for the prophylactic (preventer) management of mild, moderate, and severe asthma in adults and children aged 5 years and over. By controlling underlying airway inflammation, it reduces the frequency of symptoms, the need for reliever medication, and the risk of asthma exacerbations. It is the recommended first-line inhaled corticosteroid (ICS) option in the BTS/NICE/SIGN UK asthma guidelines for many patients.
Used as part of long-term step-up therapy in patients whose asthma is not adequately controlled on reliever inhalers alone or on lower-dose ICS, often in combination with a long-acting beta-2 agonist (LABA) or leukotriene receptor antagonist (LTRA) at higher steps of the stepwise asthma management approach.
Recommended in patients with frequent exacerbations or rescue oral corticosteroid courses, where higher-dose inhaled corticosteroid maintenance therapy can reduce both exacerbation frequency and reliance on systemic steroids. Clenil 200 mcg is often used in this setting.
In children aged 5 years and over, low-dose Clenil Modulite (typically 100–200 mcg/day) is used to control persistent symptoms, reduce reliever use, and protect against exacerbations. Growth should be monitored periodically, given the small but real risk of growth velocity reduction with prolonged inhaled corticosteroid use.
Clenil Modulite controls underlying airway inflammation and reduces the frequency of asthma symptoms and attacks. It does not cure asthma or reverse established airway remodelling. Optimal asthma care combines daily preventer treatment with a personalised asthma action plan, regular reviews, identification and avoidance of triggers, and good inhaler technique — ideally with the use of a spacer device.
How Does Clenil Modulite Work?
Clenil Modulite delivers beclometasone dipropionate, a synthetic halogenated glucocorticoid, directly to the bronchial airways via a pressurised metered-dose inhaler using the HFA (hydrofluoroalkane) Modulite propellant system. The medication acts locally in the lungs to suppress airway inflammation — the core pathological process driving asthma symptoms.
Prodrug activation in the lung: Beclometasone dipropionate is a prodrug that is rapidly hydrolysed by esterase enzymes in lung tissue to its active metabolite, beclometasone 17-monopropionate. This metabolite has approximately 25 times the affinity for the glucocorticoid receptor compared to the parent compound, accounting for the high local anti-inflammatory potency in the airways.
Glucocorticoid receptor activation and gene regulation: Active beclometasone diffuses across airway epithelial and inflammatory cell membranes, binds intracellular glucocorticoid receptors, and the receptor-ligand complex translocates to the nucleus. There it modulates the transcription of genes governing the inflammatory response — suppressing the production of pro-inflammatory cytokines (IL-4, IL-5, IL-13, TNF-α), reducing leukocyte recruitment (eosinophils, T-lymphocytes, mast cells) into the airway wall, inhibiting phospholipase A2 (reducing prostaglandin and leukotriene synthesis), and promoting the transcription of anti-inflammatory mediators.
Resulting clinical effects: Reduced airway wall oedema, decreased mucus production, attenuation of bronchial hyper-reactivity, and reduced frequency and severity of asthma symptoms. With consistent daily use, Clenil reduces the need for reliever inhalers, cuts the risk of asthma exacerbations, and helps preserve long-term lung function.
Local versus systemic action: Most of the inhaled dose acts locally in the airways, with only modest systemic absorption. However, swallowed drug (the portion deposited in the mouth and throat) and absorbed pulmonary drug contribute some systemic exposure, which becomes clinically relevant at high doses or with prolonged use.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Use Clenil Modulite every day, even when you feel well. It is a preventer inhaler that controls underlying airway inflammation; its benefit depends on consistent daily use. Stopping or skipping doses allows inflammation to return and increases the risk of attacks.
Take your usual dose morning and evening, ideally at the same times each day. Build the inhaler into a fixed routine (such as alongside teeth brushing) to help with adherence.
Rinse your mouth and gargle with water (then spit it out) after each dose. This significantly reduces the risk of oral thrush and hoarseness, the two most common local side effects.
Consider using a spacer device, particularly in children, the elderly, and anyone who finds it difficult to coordinate breathing with the inhaler. A spacer increases the proportion of the dose reaching the lungs and reduces oropharyngeal deposition.
Shake the inhaler before each use and check the dose counter regularly so that you do not run out unexpectedly.
Always carry a fast-acting reliever inhaler (such as salbutamol) for acute symptoms. Clenil does not provide rescue relief.
Do not stop Clenil suddenly after long-term use. Any reduction in dose should be made gradually under clinical supervision once your asthma is well controlled.
Side Effects of Clenil Modulite
Most side effects are local (affecting the mouth and throat) and largely preventable with good inhaler technique. Systemic side effects are uncommon at standard doses but become more likely with high-dose, prolonged treatment.
- Oral candidiasis (oral thrush) — reduced by rinsing the mouth after use
- Dysphonia (hoarseness or change in voice)
- Throat irritation
- Cough on inhalation
- Headache
- Mild taste disturbance
- Paradoxical bronchospasm — sudden worsening of wheeze and breathlessness immediately after inhalation; rare; requires stopping Clenil, using reliever inhaler, and urgent clinical review
- Severe allergic reactions — angioedema, anaphylaxis; very rare
- Adrenal suppression and Cushingoid features — with prolonged high-dose use; risk highest at doses >1000 mcg/day in adults or proportionally lower in children
- Growth velocity reduction in children — small but measurable; height should be monitored periodically in children on long-term treatment
- Reduced bone mineral density — with prolonged high-dose use, particularly in older adults
- Cataract and glaucoma — small increased risk reported with prolonged ICS use, particularly in those with pre-existing risk factors
- Psychological and behavioural effects — rare; particularly in children; psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression
- Pneumonia — small increased risk reported in COPD patients on ICS; less clearly established in asthma
The most important local side effects — oral candidiasis and dysphonia — are very common and bother many patients. Both are dramatically reduced by two simple measures: rinsing the mouth and gargling with water (then spitting it out) immediately after every inhalation, and using a spacer device with the inhaler. Both interventions should be explicitly discussed with every patient starting an inhaled corticosteroid, regardless of dose.
Drug Interactions
Although inhaled corticosteroids have far lower systemic exposure than oral steroids, clinically significant interactions can occur, particularly with strong CYP3A4 inhibitors. Always disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Clenil Modulite.
Strong inhibitors of cytochrome P450 3A4 — including ritonavir-boosted antiretrovirals, cobicistat-containing HIV regimens, itraconazole, ketoconazole, and clarithromycin — can substantially increase systemic exposure to beclometasone and its active metabolite, raising the risk of systemic corticosteroid effects (including Cushingoid features and adrenal suppression). Co-administration should be avoided where possible, or only undertaken with explicit clinical risk-benefit assessment and patient monitoring.
Concurrent use of Clenil Modulite with oral, intramuscular, or intravenous corticosteroids — for example during severe asthma exacerbations or for other inflammatory conditions — compounds the systemic corticosteroid burden and increases the risk of adrenal suppression, osteoporosis, glucose intolerance, and other systemic steroid effects. Where dual therapy is required, the lowest effective doses should be used and patients monitored.
Beta-blockers (both non-selective and cardioselective) can precipitate bronchospasm in patients with asthma and may attenuate the bronchodilator response to short-acting beta-2 agonists used for relief. They are generally contraindicated in asthma. Patients receiving Clenil Modulite for asthma should disclose any beta-blocker therapy to their prescribing clinician.
Inhaled corticosteroids modestly suppress local immunity in the oropharynx and lower airways. This may increase the risk of opportunistic infections such as oral candidiasis, and — with high-dose long-term use — may attenuate the response to live attenuated vaccines (MMR, varicella, BCG, yellow fever). Routine inhaled corticosteroid use does not contraindicate live vaccines, but vaccination timing should be discussed with a clinician.
Important Warnings
Clenil Modulite is a preventer inhaler, not a reliever. It does not relieve acute breathlessness or wheeze and must not be used to treat an asthma attack. Every patient on Clenil must also have a fast-acting reliever inhaler (such as salbutamol) available at all times. If reliever use is increasing, or symptoms are worsening, seek urgent medical advice.
Inhaled corticosteroids can cause oral candidiasis (oral thrush) and dysphonia (hoarseness), particularly at higher doses. The risk is significantly reduced by rinsing the mouth and gargling with water (and spitting it out) immediately after each inhalation, and by using a spacer device with the metered-dose inhaler.
High-dose long-term inhaled corticosteroids can produce systemic effects — including adrenal suppression, reduced bone mineral density, cataract, glaucoma, and (in children) growth velocity reduction. The dose should always be titrated to the lowest level at which effective asthma control is maintained. In children on prolonged treatment, growth should be monitored regularly.
Rarely, inhaled medications can cause paradoxical bronchospasm — a sudden worsening of wheeze and breathlessness immediately after inhalation. If this happens, stop using Clenil, use your reliever inhaler, and contact your clinician urgently. Treatment will need to be reviewed and a different inhaler may be prescribed.
Do not stop Clenil Modulite suddenly, particularly after long-term or high-dose use, as this can cause your asthma to deteriorate and may unmask adrenal suppression. Any change to your inhaler treatment should be made gradually under clinical supervision.
Use during pregnancy and breastfeeding is generally considered acceptable when asthma is well controlled, because uncontrolled asthma poses a greater risk to both mother and baby than inhaled corticosteroid use. The lowest effective dose should be used. Always discuss inhaler treatment in pregnancy or breastfeeding with your clinician.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Clenil Modulite FAQs
Clenil Modulite is a preventer inhaler containing beclometasone dipropionate, an inhaled corticosteroid. It is used every day to control the underlying inflammation in your airways and reduce the frequency of asthma symptoms and attacks. It is not a reliever inhaler — it will not help an acute asthma attack — and must be used regularly to be effective.
The dose depends on your age and the severity of your asthma. Adults with mild-to-moderate asthma typically take 100–400 mcg twice daily (200–800 mcg/day total); higher doses up to 2000 mcg/day may be used in severe asthma under specialist supervision. Children aged 5 and over typically take 50–200 mcg twice daily. Always follow the specific dose your clinician has prescribed.
Clenil starts to reduce airway inflammation within days of starting regular use, but the full benefit may take 1–2 weeks to develop. It must be taken every day as prescribed, even when you feel well, to maintain control of your asthma. Stopping or skipping doses allows airway inflammation to return and increases the risk of attacks.
Always rinse your mouth thoroughly with water and gargle (then spit it out) immediately after each dose. This significantly reduces the risk of oral thrush and hoarseness. Using a spacer device with the inhaler also reduces deposition in the mouth and throat and improves the dose reaching the lungs.
No — Clenil is a preventer inhaler, not a reliever. It does not relieve acute breathlessness or wheeze and must not be used during an asthma attack. You should always carry a fast-acting reliever inhaler (such as salbutamol) for acute symptoms, and seek urgent medical advice if your symptoms are not responding to your reliever, you need it more than usual, or your peak flow is dropping.
Asthma is generally safe to treat in pregnancy with inhaled corticosteroids, and good asthma control is important for both you and your baby. Uncontrolled asthma poses greater risks than the medication itself. Most clinicians continue Clenil during pregnancy and breastfeeding at the lowest effective dose, but you should discuss your treatment plan with your clinician.
If you forget a dose, take it as soon as you remember unless it is nearly time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not double up on the next dose. Consistent daily use is important, so try to build the inhaler into your morning and evening routine.
Do not stop Clenil suddenly without speaking to your clinician, particularly if you have been taking it long term or at high doses. Stopping abruptly can cause your asthma to deteriorate and may unmask adrenal suppression. Your clinician will help you step down the dose gradually if appropriate.